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Abstract
Background The purpose of the present study was to analyse the impact of patient-related risk factors and medi-
cation drugs on haemorrhagic complications following cholecystectomy.
Methods All cholecystectomies registered in the Swedish population-based Register for Gallstone Surgery and
ERCP (GallRiks) were identified. Risk factors for bleeding were assessed by linking data in the GallRiks to the
National Patient Register and the Prescribed Drug Register, respectively. The risk of haemorrhage leading to
intervention was determined by variable regression, and Kaplan–Meier analysis assessed survival rate following
perioperative haemorrhage.
Results A total of 94,557 patients were included between 2005 and 2015, of which 799 (0.8%) and 1192 (1.3%)
patients were registered as having perioperative and post-operative haemorrhage, respectively. In multivariable
analysis, an increased risk of haemorrhagic complications was seen in patients with cerebrovascular disease
(p = 0.001), previous myocardial infarction (p = 0.001), kidney disease (p = 0.001), heart failure (p = 0.001),
diabetes (p = 0.001), peripheral vascular disease (p = 0.004), and obesity (p = 0.005). Prescription of tricyclic
antidepressant (p = 0.018) or dipyridamole (p = 0.047) was associated with a significantly increased risk of peri-
operative haemorrhage. However, this increase in risk did not remain significant following Bonferroni correction for
mass significance. Perioperative haemorrhage increased the risk of death occurring within the first post-operative year
[Hazard Ratio, (HR) 4.9, CI 3.52–6.93] as well as bile duct injury (OR 2.45, CI 1.79–3.37).
Conclusion The increased risk of haemorrhage associated with comorbidity must be taken into account when
assessing patients prior to cholecystectomy. Perioperative bleeding increases post-operative mortality and is asso-
ciated with an increased risk of bile duct injury.
Introduction
Laparoscopic cholecystectomy (LC) has since its intro-
duction in the 1990s become the golden standard for the
surgical treatment of symptomatic gallstone disease. In
Sweden, about 13,000 cholecystectomies are performed
each year of which 90% are performed with laparoscopic
technique [1]. In LC, bile duct injuries and haemorrhage
are the most feared complications. However, major
haemorrhage is a rare event (0.08–0.25%) and is most often
caused by injury to the right hepatic artery or inadvertent
placement of a trocar in the aorta or vena cava [2–4]. More
frequently occurring are minor bleeds arising from the
abdominal wall and the liver bed following cholecystec-
tomy (2.0–4.1%) [5, 6]. Haemorrhage from small vessels
complicates the surgical procedure, increases the risk of
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conversion [7], and in some cases requires reoperation and/
or blood transfusion [5].
Risk scoring systems based on comorbidity has been
developed in order to predict bleeding risk. Furthermore,
conditions such as renal and heart failure have been found to
be associated with increased risk of haemorrhagic compli-
cations [8, 9]. In order to minimize the risk of procedure-
related bleeding, drugs with anticoagulant or antiaggregant
effects are usually discontinued. However, not often con-
sidered there are other drugs with side effects that might
inadvertently affect platelet function and/or coagulation
factors leading to impaired clotting ability [10, 11].
The influence of patient comorbidity and drugs on
haemorrhagic complications in cholecystectomy is insuffi-
ciently known. We therefore undertook a population-based
study to assess comorbidity as an independent risk factor for
haemorrhagic complications. Furthermore, in the context of
reducing haemorrhagic complications, a second part of the
study aimed to investigate the need for the discontinuation of
prescription drugs prior to cholecystectomy.
Methods
Study design
All laparoscopic and open cholecystectomy procedures
registered between 2006 and 2015 in the Swedish
Register for Gallstone Surgery and ERCP (GallRiks) [12]
were included in the study. Every Swedish citizen has a
unique National Registration Number (NRN) [13]. In
order to assess the impact of prescribed drugs on risk of
haemorrhage, the NRN was used as an aid in cross-
matching the GallRiks with the Swedish Prescribed Drug
Register (PDR; Swedish: La¨kemedelsregistret) [14]. Only
drugs prescribed to patients within 90 days prior to sur-
gery were included in the analysis. The association of
comorbidity with risk of bleeding was studied by com-
paring data from the GallRiks with the National Patient
Register (NPR; Swedish: Patientregistret). Data in Gall-
Riks were linked to the Swedish Death Register to obtain
ICD codes indicating cause of death. Mortality was only
considered to be procedure-related if a complication was
registered on the death certificate as primary or con-
tributing diagnosis.
Definitions
Data regarding perioperative haemorrhage were obtained
from the GallRiks. Perioperative haemorrhage was
defined as blood loss during the procedure that led to
conversion to open surgery, blood transfusion, or other
intervention not routinely applied in gallstone surgery. A
post-operative haemorrhage was defined as bleeding
within 30 days after cholecystectomy that necessitated
reoperation, blood transfusion, or resulted in prolonged
hospital stay ([1 day longer than the median stay). The
post-operative incidence was based on those patients
registered in the GallRiks and/or PAR as having had a
post-operative haemorrhage. The occurrence of haemor-
rhage in the peri- and/or post-operative period within
30 days following cholecystectomy was given the term
‘‘total bleed’’. Bile duct injury was defined as injury and/
or clinically significant leakage detected in the peri- and/
or post-operative period.
Data sources
The main purpose of the GallRiks is to assemble infor-
mation, serve as a base for quality assurance, and facilitate
research regarding gallstone surgery and ERCP. The reg-
ister was started in 2005 and has today reached full national
coverage ([90%). There are currently 79 hospitals/units in
Sweden enrolled in the GallRiks. Repeated annual valida-
tion assures high-quality data with correctness in
97.2–98.2% of all registrations [15]. Data assembly in the
GallRiks have previously been described in detail [16].
The population-based PDR has registered dispensed
medication in Sweden since July 2005. All drugs pre-
scribed are classified according to the Anatomical Thera-
peutic Chemical (ATC) classification system. Information
on dose and date of dispensing of all prescribed drugs
dispensed at Swedish pharmacies is registered in the PDR.
However, the register contains no information regarding
drugs administered during in-hospital treatment, over-the-
counter (OTC) drugs (without prescription), or drugs
administered in day care. In July–December 2005, the PDR
registered 84% of the nation’s total consumption of drugs
and 77% of the total expenditure [17].
The NPR was founded in 1964 and provides information
and discharge diagnosis for all hospital admissions and out-
patients in Sweden. With nationwide coverage, the NPR
contains information on over 50 million patients since its
inception. Diagnoses in the NPR are coded according the ICD
system and currently over 99% of all discharges are covered
[18]. The validity of the register has been tested by Lud-
wigsson et al. [19] showing a high accuracy (85–95%) for
most diagnoses.
Statistical analysis
The Chi-square test was used to compare patient charac-
teristics. Univariate analysis was undertaken in order to
identify predictors of haemorrhage with estimates of odds
ratio (OR) and 95 per cent confidence intervals. In order to
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restrict confounding to a minimum, all variables in the
multivariate regression analyses of patient characteristics
were adjusted for gender, age, ASA, surgical indication,
operative approach, thromboembolism prophylaxis, oper-
ation time, and prescribed anticoagulant medication.
The impact of prescribed drugs on bleeding was asses-
sed by univariate regression.
In this analysis, mass significance was managed by
Bonferroni correction [20], where data were considered
significant at the 95% level if the p value divided by the
number of drugs in the analysis (n = 28) was less than
p = 0.05/28 = 0.002. Kaplan–Meier analysis assessed the
overall survival following a registered haemorrhagic
complication. Hazard ratios (HRs) were estimated using
the Cox regression model. Gender, age, indication, oper-
ative approach, and ASA classification were added as
covariables in the calculation of adjusted HR. All statis-




Altogether 94,557 patients registered in the GallRIks
undergoing cholecystectomy (laparoscopic as well as
open) 2005–2015 were included in the study. The total
incidence of post-operative complications was 8.4% (7975
patients). Perioperative haemorrhage was registered in
799 (0.8%). The incidence of post-operative haemorrhage
was 1.3% (1192 patients). There was 46.8% agreement in
frequency of post-operative haemorrhage between the
registers. The majority of post-operative complications
registered in the GallRiks occurred within 30 days after
surgery (n = 779, 97%). Bleeding was also registered
between 30 and 60 days (n = 18, 2.25%) and between 60
and 90 days (n = 6, 0.75%). In total, 1867 patients were
registered with a peri- and/or post-operative intervention
due to haemorrhage, resulting in a total bleeding inci-
dence of 2.0%. Haemorrhagic shock was registered in 10
patients (0.01%).
Risk factors
Risk factors for haemorrhage in univariate regression
(Table 1) were: male gender; high age; ASA[ I; gallstone
complications; conversion to open surgery; open chole-
cystectomy; thromboembolism prophylaxis; and long
operation time. A subgroup analysis was conducted on
36,797 patients for whom BMI was registered (miss-
ing = 57,760). There were 12,334 patients (33.5%) with
BMI\ 18.5 (underweight), 13,776 patients (37.4%) with
BMI 18.5–24.9 (normal weight), 9702 (26.4%) patients
with BMI 25–29.9 (overweight), and 985 patients (2.7%)
with BMI[ 30 (obesity). The odds ratio for BMI C 25
and bleeding was 1.04, (CI 0.89–1.23, data not shown).
However, in the multivariate analysis, obesity was a sig-
nificant risk factor for bleeding (OR = 1.3, CI 1.10–1.56).
In Table 2, 28 prescription drugs with known antico-
agulant or antiplatelet effect were tested for association
with bleeding. In the univariate analysis, dipyridamole
(n = 252, OR = 2.39, CI 0.98–5.81) and tricyclic antide-
pressants (TCA, n = 1151. OR = 1.78, CI 1.10–2.89) had
a significantly elevated risk of perioperative haemorrhage.
This increase in risk, however, did not remain significant in
a Bonferroni correction.
Cerebrovascular disease (OR = 1.96; CI 1.64–2.34),
previous myocardial infarction (OR = 1.94, CI 1.56–2.40),
kidney disease (OR = 1.93; CI 1.41–2.63), heart failure
(OR = 1.73, CI 1.37–2.18), diabetes (OR = 1.49, CI
1.27–1.74), peripheral vascular disease (OR = 1.49, CI
1.13–1.95), and obesity (OR = 1.27, CI 1.08–1.51) were
all found to be associated with a significantly increased risk
of haemorrhagic complications (Table 3).
Bile duct injury
By including perioperative iatrogenic bile duct injury and/
or post-operative bile leakage, the overall incidence of bile
duct injury was 1.6%. For patients with perioperative
haemorrhage, the incidence of bile duct injury was sig-
nificantly higher (5.4%, p\ 0.05). Adjusting for gender,
age, indication, operative approach, and ASA classifica-
tion, perioperative bleeding was found to be a risk factor
for bile duct injury (OR = 2.45, CI 1.79–3.37).
Mortality
In total, 223 (0.24%) patients died within 30 days after
cholecystectomy. The cause of death was procedure-related
in 25 (0.03%). In patients with perioperative, post-operative,
and total bleeding, 16 patients (2.0%), 25 patients (11.2%),
and 34 patients (15.2%) died, respectively. Almost half of
patients (48%) with a procedure-related cause of death had a
haemorrhage registered prior to death. Patients that had a
perioperative haemorrhage had a significantly increased
mortality during the first post-operative year (Fig. 1). The
increased hazard of death (HR) associated with periopera-
tive bleeding was estimated to be 4.9 (CI 3.52–6.93) with an
adjusted HR of 1.8 (CI 1.28–2.53). The increased mortality
in patients with a perioperative haemorrhage remained when
performing a subgroup analysis where death within thirty

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2 Prescribed drugs1 and haemorrhagic complications
Drug N (%) Periop bleed (%) p Postop bleed p Total bleed2 (%) p
Acetysalicylic acid 7443 (8.75) 61 (8.5) 0.81 106 (9.68) 0.27 159 (9.36) 0.36
ACE inhibitor 6575 (7.73) 53 (7.38) 0.73 80 (7.31) 0.60 126 (7.42) 0.63
Apixaban 11 (0.01) 0 (0) n.s 0 (0) n.s 0 (0) n.s
Azathioprin 179 (0.21) 0 (0) n.s 0 (0) n.s 0 (0) n.s
Acyclovir 198 (0.23) 2 (0.28) 0.80 2 (0.18) 0.22 4 (0.24) 0.98
Beta-lactam antibiotics 4790 (5.63) 51 (7.10) 0.09 63 (5.75) 0.86 101 (5.95) 0.56
Calcium channel inhibitor 6146 (7.22) 60 (8.40) 0.24 76 (6.94) 0.72 130 (7.66) 0.49
Carboxamide 361 (0.42) 1 (0.14) 0.24 2 (0.18) 0.22 3 (0.18) 0.11
Cephalosporin 31 (0.04) 0 (0) n.s 1 (0.10) 0.34 1 (0.06) 0.62
Clopidogrel 565 (0.66) 7 (0.97) 0.30 4 (0.37) 0.22 11 (0.65) 0.93
Cytostatic agents 238 (0.28) 3 (0.42) 0.48 6 (0.55) 0.09 7 (0.41) 0.30
Dabigatran 37 (0.04) 1 (0.14) 0.22 0 (0) n.s 1 (0.06) 0.76
Dipyridamole 252 (0.30) 5 (0.70) 0.05* 1 (0.10) 0.21 6 (0.35) 0.66
Heparin 838 (0.98) 7 (0.97) 0.98 11 (1.0) 0.95 15 (0.88) 0.67
Kinin 58 (0.07) 0 (0) n.s 0 (0) n.s 0 (0) n.s
NSAID 7932 (9.32) 73 (10.2) 0.43 102 (9.32) 1.0 163 (9.60) 0.69
Phenytoin 77 (0.09) 0 (0) n.s 2 (0.18) 0.31 2 (0.12) 0.71
Prasugrel 5 (0.01) 0 (0) n.s 0 (0) n.s 0 (0) n.s
Rifampicin 16 (0.02) 0 (0) n.s 1 (0.10) 0.08 1 (0.06) 0.22
Rivaroxaban 23 (0.03) 0 (0) n.s 0 (0) n.s 0 (0) n.s
SSRI 5203 (6.11) 45 (6.27) 0.86 67 (6.12) 0.99 106 (6.24) 0.82
Statin 7377 (8.67) 58 (8.10) 0.57 108 (9.86) 0.16 157 (9.25) 0.39
Thiazide 2355 (2.77) 25 (3.48) 0.24 31 (2.83) 0.90 55 (3.24) 0.23
Ticagrelor 32 (0.04) 0 (0) n.s 1 (0.10) 0.36 1 (0.06) 0.65
Tricyclic antidepressant 1151 (1.35) 17 (2.37) 0.02* 18 (1.64) 0.40 32 (1.88) 0.055
Trimethoprim/sulphamethoxazole 255 (0.30) 4 (0.56) 0.21 4 (0.37) 0.69 6 (0.35) 0.68
Valproate 210 (0.25) 2 (0.28) 0.86 0 (0) n.s 2 (0.12) 0.28
Warfarin 1818 (2.14) 21 (2.92) 0.14 27 (2.47) 0.45 45 (2.70) 0.14
Table 2: Pearson´s Chi-Square test
* Significant within 95% confidence interval
1 Drugs prescribed within 90 days prior to surgery
2 Total haemorrhage (peri- and/or post-operative) for each drug
Table 3 Comorbidity and haemorrhagic complications1
Condition N (%) Bleed (%) Univariate Multivariate
p OR CI p OR CI
Cerebrovascular disease 3283 (3.48) 151 (4.60) 0.001 2.52 2.12–2.98 0.001 1.96 1.64–2.34
Diabetes 5396 (5.71) 197 (3.65) 0.001 1.99 1.71–2.31 0.001 1.49 1.27–1.74
Heart failure 1797 (1.90) 103 (5.73) 0.001 3.14 2.56–3.85 0.001 1.73 1.37–2.18
Kidney disease 788 (0.83) 48 (6.10) 0.001 3.28 2.44–4.41 0.001 1.93 1.41–2.63
Liver cirrhosis 345 (0.37) 14 (4.10) 0.005 2.11 1.23–3.61 0.053 1.71 0.99–2.94
Lung disease 8750 (9.27) 181 (2.10) 0.51 1.05 0.90–1.23 0.363 0.930 0.79–1.09
Obesity 6173 (6.54) 157 (2.54) 0.01 1.32 1.12–1.56 0.005 1.27 1.08–1.51
Peripheral vascular disease 1314 (1.40) 64 (4.87) 0.001 2.60 2.01–3.35 0.004 1.49 1.13–1.95




In this population-based study, cerebrovascular disease,
previous myocardial infarction, kidney disease, heart fail-
ure, diabetes, peripheral vascular disease, and obesity were
all found to be independent risk factors for haemorrhagic
complications in cholecystectomy. Furthermore, patients
with perioperative haemorrhage had a fivefold increase in
hazard ratio for post-operative death. Perioperative bleed-
ing significantly increased the risk of bile duct injury.
Strength and weakness
The strength that this study presents is the population-
based design, with data retrieved from three validated
Swedish quality registers. Other strengths are that haem-
orrhage was presented as perioperative, post-operative as
well as total. Our definition of haemorrhage in this study
was a bleed that mandated intervention. It could be argued,
however, that a more stringent way of defining a haemor-
rhage would be a minimum volume of blood loss.
There are some potential weaknesses with the present
study. Data on prescribed drugs did not provide informa-
tion on if, or for how long the drug was discontinued prior
to surgery. In this study, the assessment of potent antico-
agulants such as Warfarin and new oral anticoagulants
(NOACs) was difficult since it was unlikely to believe that
these drugs would have been continued during surgery.
Furthermore, the timing of surgery after interrupting the
anticoagulant treatment may also affect the risk of bleed-
ing. Since we do not have any data on this, we are not able
to determine the optimal interval to perform surgery after
anticoagulant cessation.
Another weakness was the lack of precision in comor-
bidity diagnoses. For instance, ‘‘kidney disease’’ is a group
diagnosis made up from a number of kidney disorders.
Furthermore, registers on surgical procedures that are based
on self-reported adverse events are inevitably subject to
selection bias since it is more likely that a positive outcome
of surgery is reported. This effect is lessened by repeated
validation. Surgical units enrolled in GallRiks are continu-
ously visited by appointed inspectors, and during these
validations, data from medical journals are scrutinized and
compared with those entered in the register. Previous cross-
check control of data has found less than 2% error [15].
Comparison with other studies
The overall incidence of haemorrhage during and within
30 days after cholecystectomy was 2.0%. Due to differ-
ences in criteria, the comparison of haemorrhage rates
between different studies must be interpreted with caution.
Shea et al. [21] reported in a meta-analysis a bleeding
complication rate of 10.5% and Z´graggen reported a peri-
operative haemorrhage incidence of 1.97% [7]. In a study
by Ercan et al., patients taking oral anticoagulants (OACs)
were taken off their medication prior to cholecystectomy
and given enoxaparin (low molecular heparin) bridging
therapy and compared to a control group. In the OAC
group, the post-operative bleeding rate was 25% compared
to 1.5% in the control group [22].
In accordance with previous studies [7, 21, 23, 24], we
found that the overall 30-day mortality following chole-
cystectomy is low (0.24%). However, haemorrhage leading
to intervention increased mortality by over 60 times com-
pared to patients without bleeding complications. Further-
more, half of all patients that died in the post-operative
period from procedure-related causes were registered as
having a haemorrhage prior to death. A Kaplan–Meier
estimate also showed that survival of patients who had a
perioperative haemorrhage continued to decline beyond the
30-day post-operative interval.
Serotonin plays an important role in the process of
platelet aggregation and vasoconstriction during primary
haemostasis [25]. Indeed, by reducing the re-uptake of
serotonin, TCA inhibits platelet aggregation [26] and has
been associated with an elevated bleeding risk [27, 28]. In
our study, tricyclic antidepressants (TCA) significantly
increased the risk of perioperative haemorrhage. However,
the correlation did not tolerate a Bonferroni correction,
indicating that the result could be an artefact of mass sig-
nificance. Nevertheless, TCA may have a clinically rele-
vant impact on the risk of haemorrhage that should be
evaluated in future studies.




Following cholecystectomy, it has been shown that a
significant number of patients with bile duct injuries have
an associated vascular injury [29, 30]. These ‘‘vasculobil-
iary’’ injuries are often managed at tertiary care facilities
[30]. Risk factors for biliary injury during cholecystectomy
have previously been described in detail [31]. However, to
the best of our knowledge, perioperative bleeding has not
been defined as a significant risk factor for bile duct injury.
As previously reported, bile duct injuries may occur as a
consequence of a bleeding-impaired exposure and visual-
ization during dissection in cholecystectomy [32].
It is reasonable to believe that a perioperative haemor-
rhage distorts anatomical landmarks, resulting in an
increased risk of iatrogenic bile duct injury or misplace-
ment of clips. In order to account for all possible injuries to
the bile ducts, we chose a broader definition for bile duct
injury including both iatrogenic injuries detected during the
operation and/or bile leaks in the post-operative phase. This
resulted in a higher incidence of bile duct injuries than
previously reported [4, 7]. In the present study, perioper-
ative bleeding was associated with an increased incidence
of injury and/or bile leakage. Moreover, in a multivariable
regression model, perioperative bleeding was a strong
predictor of bile duct injury.
Conclusion
Patient comorbidity needs to be taken into account when
assessing the risk of haemorrhage and peri-operative
bleeding increases the risk of death following cholecys-
tectomy. However, our results suggest that commonly
prescribed medication does not need to be discontinued in
order to reduce haemorrhagic complications. Finally, sur-
geons need to be aware of the increased risk of biliary duct
injury following haemorrhage and should consider con-
verting to open surgery if visualization and exposure is
inadequate.
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